Drak2 is not required for tumor surveillance and suppression

Benjamin A. Edwards, Tarsha L. Harris, Helen Floersh, John R. Lukens, Md Hasan Zaki, Peter Vogel, Thirumala Devi Kanneganti, Jack D. Bui, Maureen A. McGargill

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Drak2 is a promising therapeutic target to treat organ-specific autoimmune diseases such as type 1 diabetes and multiple sclerosis without causing generalized immune suppression. Inhibition of Drak2 may also prevent graft rejection following organ transplantation. However, Drak2 may function as a critical tumor suppressor, which would challenge the prospect of targeting Drak2 for therapeutic treatment. Thus, we examined the susceptibility of Drak2<sup>-/-</sup> mice in several tumor models. We show that Drak2 is not required to prevent tumor formation in a variety of settings. Therefore, Drak2 does not function as an essential tumor suppressor in in vivo tumor models. These data further validate Drak2 as a viable therapeutic target to treat autoimmune disease and graft rejection. Importantly, these data also indicate that while Drak2 may induce apoptosis when overexpressed in cell lines, it is not an essential tumor suppressor.

Original languageEnglish (US)
Pages (from-to)161-166
Number of pages6
JournalInternational Immunology
Volume27
Issue number3
DOIs
StatePublished - 2015

Fingerprint

Neoplasms
Graft Rejection
Autoimmune Diseases
Organ Transplantation
Type 1 Diabetes Mellitus
Multiple Sclerosis
Therapeutics
Apoptosis
Cell Line

Keywords

  • Autoimmunity
  • Regulation of immune responses
  • Tumor surveillance

ASJC Scopus subject areas

  • Immunology

Cite this

Edwards, B. A., Harris, T. L., Floersh, H., Lukens, J. R., Zaki, M. H., Vogel, P., ... McGargill, M. A. (2015). Drak2 is not required for tumor surveillance and suppression. International Immunology, 27(3), 161-166. https://doi.org/10.1093/intimm/dxu146

Drak2 is not required for tumor surveillance and suppression. / Edwards, Benjamin A.; Harris, Tarsha L.; Floersh, Helen; Lukens, John R.; Zaki, Md Hasan; Vogel, Peter; Kanneganti, Thirumala Devi; Bui, Jack D.; McGargill, Maureen A.

In: International Immunology, Vol. 27, No. 3, 2015, p. 161-166.

Research output: Contribution to journalArticle

Edwards, BA, Harris, TL, Floersh, H, Lukens, JR, Zaki, MH, Vogel, P, Kanneganti, TD, Bui, JD & McGargill, MA 2015, 'Drak2 is not required for tumor surveillance and suppression', International Immunology, vol. 27, no. 3, pp. 161-166. https://doi.org/10.1093/intimm/dxu146
Edwards, Benjamin A. ; Harris, Tarsha L. ; Floersh, Helen ; Lukens, John R. ; Zaki, Md Hasan ; Vogel, Peter ; Kanneganti, Thirumala Devi ; Bui, Jack D. ; McGargill, Maureen A. / Drak2 is not required for tumor surveillance and suppression. In: International Immunology. 2015 ; Vol. 27, No. 3. pp. 161-166.
@article{d5b49843c54c4daf862158112fe3a439,
title = "Drak2 is not required for tumor surveillance and suppression",
abstract = "Drak2 is a promising therapeutic target to treat organ-specific autoimmune diseases such as type 1 diabetes and multiple sclerosis without causing generalized immune suppression. Inhibition of Drak2 may also prevent graft rejection following organ transplantation. However, Drak2 may function as a critical tumor suppressor, which would challenge the prospect of targeting Drak2 for therapeutic treatment. Thus, we examined the susceptibility of Drak2-/- mice in several tumor models. We show that Drak2 is not required to prevent tumor formation in a variety of settings. Therefore, Drak2 does not function as an essential tumor suppressor in in vivo tumor models. These data further validate Drak2 as a viable therapeutic target to treat autoimmune disease and graft rejection. Importantly, these data also indicate that while Drak2 may induce apoptosis when overexpressed in cell lines, it is not an essential tumor suppressor.",
keywords = "Autoimmunity, Regulation of immune responses, Tumor surveillance",
author = "Edwards, {Benjamin A.} and Harris, {Tarsha L.} and Helen Floersh and Lukens, {John R.} and Zaki, {Md Hasan} and Peter Vogel and Kanneganti, {Thirumala Devi} and Bui, {Jack D.} and McGargill, {Maureen A.}",
year = "2015",
doi = "10.1093/intimm/dxu146",
language = "English (US)",
volume = "27",
pages = "161--166",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Drak2 is not required for tumor surveillance and suppression

AU - Edwards, Benjamin A.

AU - Harris, Tarsha L.

AU - Floersh, Helen

AU - Lukens, John R.

AU - Zaki, Md Hasan

AU - Vogel, Peter

AU - Kanneganti, Thirumala Devi

AU - Bui, Jack D.

AU - McGargill, Maureen A.

PY - 2015

Y1 - 2015

N2 - Drak2 is a promising therapeutic target to treat organ-specific autoimmune diseases such as type 1 diabetes and multiple sclerosis without causing generalized immune suppression. Inhibition of Drak2 may also prevent graft rejection following organ transplantation. However, Drak2 may function as a critical tumor suppressor, which would challenge the prospect of targeting Drak2 for therapeutic treatment. Thus, we examined the susceptibility of Drak2-/- mice in several tumor models. We show that Drak2 is not required to prevent tumor formation in a variety of settings. Therefore, Drak2 does not function as an essential tumor suppressor in in vivo tumor models. These data further validate Drak2 as a viable therapeutic target to treat autoimmune disease and graft rejection. Importantly, these data also indicate that while Drak2 may induce apoptosis when overexpressed in cell lines, it is not an essential tumor suppressor.

AB - Drak2 is a promising therapeutic target to treat organ-specific autoimmune diseases such as type 1 diabetes and multiple sclerosis without causing generalized immune suppression. Inhibition of Drak2 may also prevent graft rejection following organ transplantation. However, Drak2 may function as a critical tumor suppressor, which would challenge the prospect of targeting Drak2 for therapeutic treatment. Thus, we examined the susceptibility of Drak2-/- mice in several tumor models. We show that Drak2 is not required to prevent tumor formation in a variety of settings. Therefore, Drak2 does not function as an essential tumor suppressor in in vivo tumor models. These data further validate Drak2 as a viable therapeutic target to treat autoimmune disease and graft rejection. Importantly, these data also indicate that while Drak2 may induce apoptosis when overexpressed in cell lines, it is not an essential tumor suppressor.

KW - Autoimmunity

KW - Regulation of immune responses

KW - Tumor surveillance

UR - http://www.scopus.com/inward/record.url?scp=84929016718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929016718&partnerID=8YFLogxK

U2 - 10.1093/intimm/dxu146

DO - 10.1093/intimm/dxu146

M3 - Article

C2 - 25568303

AN - SCOPUS:84929016718

VL - 27

SP - 161

EP - 166

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 3

ER -